Tailored Antiplatelet Therapy Versus Recommended Dose of Prasugrel (ANTARCTIC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01538446
Recruitment Status : Completed
First Posted : February 24, 2012
Last Update Posted : January 11, 2017
Eli Lilly and Company
Daiichi Sankyo, Inc.
Allies in Cardiovascular Trials Initiatives and Organized
Accumetrics, Inc.
Information provided by (Responsible Party):
Assistance Publique - Hôpitaux de Paris

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : May 2016
  Actual Study Completion Date : May 2016
Publications of Results:
Publications automatically indexed to this study by Identifier (NCT Number):